Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Desc)]
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
2014
Athyros, V. G., Katsiki N., & Rizzo M. (2014).  Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!. Curr Med Res Opin. 30(12), 2425-8.
Athyros, V. G., & Mikhailidis D. P. (2014).  Uric acid, chronic kidney disease and type 2 diabetes: a cluster of vascular risk factors.. J Diabetes Complications. 28(2), 122-3.
2015
Athyros, V. G., Tziomalos K., Katsiki N., Doumas M., Karagiannis A., & Mikhailidis D. P. (2015).  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.. World J Gastroenterol. 21(22), 6820-34.
Tziomalos, K., Athyros V. G., & Karagiannis A. (2015).  Cardiovascular Risk in Middle East Populations: A Call to Action.. Angiology. 66(9), 801-2.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2015).  Contrast-Induced Nephropathy: An "All or None" Phenomenon?. Angiology. 66(6), 508-13.
Athyros, V. G., Katsiki N., Karagiannis A., & Radak D. (2015).  Editorial: effect of statins on rates of long-term cardiovascular events and restenosis following carotid endarterectomy.. Curr Vasc Pharmacol. 13(2), 223-5.
Athyros, V. G., Katsiki N., & Karagiannis A. (2015).  Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease.. Curr Vasc Pharmacol. 13(3), 366-7.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII.. Curr Vasc Pharmacol. 13(6), 696-8.
Preiss, D., Campbell R. T., Murray H. M., Ford I., Packard C. J., Sattar N., et al. (2015).  The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.. Eur Heart J. 36(24), 1536-46.
Daskalopoulos, G., Karkanaki A., Piouka A., Prapas N., Panidis D., Gkeleris P., et al. (2015).  Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.. Curr Vasc Pharmacol. 13(6), 788-800.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2015).  Genetic, epidemiologic and clinical data strongly suggest that fasting or non-fasting triglycerides are independent cardiovascular risk factors.. Curr Med Res Opin. 31(3), 435-8.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus.. J Diabetes Complications. 29(1), 142-5.
Katsiki, N., Doumas M., Athyros V. G., & Karagiannis A. (2015).  Hyperuricemia as a risk factor for cardiovascular disease.. Expert Rev Cardiovasc Ther. 13(1), 19-20.
Tziomalos, K., Athyros V. G., Paschos P., & Karagiannis A. (2015).  Nonalcoholic fatty liver disease and statins.. Metabolism. 64(10), 1215-23.
Kargiotis, K., Athyros V. G., Giouleme O., Katsiki N., Katsiki E., Anagnostis P., et al. (2015).  Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.. World J Gastroenterol. 21(25), 7860-8.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention.. Curr Med Res Opin. 31(2), 191-5.
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2015).  Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly.. Atherosclerosis. 238(2), 182-4.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. Expert Opin Pharmacother. 16(10), 1449-61.
Athyros, V. G., Pagourelias E. D., Gossios T. D., & Vasilikos V. G. (2015).  Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?. Curr Vasc Pharmacol. 13(3), 368-80.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy.. Expert Rev Cardiovasc Ther. 13(9), 1059-66.
2016
Stavropoulos, K., Imprialos K. P., Boutari C., Athyros V. G., & Karagiannis A. I. (2016).  Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. J Clin Hypertens (Greenwich). 18(10), 1073.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., Athyros V. G., & Karagiannis A. I. (2016).  Current challenges in antihypertensive treatment in the elderly.. Pol Arch Med Wewn. 126(7-8), 540-51.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?. Curr Vasc Pharmacol. 14(3), 271-4.
Tziomalos, K., Athyros V. G., & Karagiannis A. (2016).  Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs.. Curr Vasc Pharmacol. 14(2), 208-10.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές